Drug Type Hormone |
Synonyms Insulin Glargine (Genetical Recombination), INSULIN GLARGINE RECOMBINANT, GLA-100 + [14] |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (20 Apr 2000), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03250 | Insulin glargine (Sanofi) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | European Union | 09 Jun 2000 | |
Diabetes Mellitus | Iceland | 09 Jun 2000 | |
Diabetes Mellitus | Liechtenstein | 09 Jun 2000 | |
Diabetes Mellitus | Norway | 09 Jun 2000 | |
Diabetes Mellitus, Type 1 | United States | 20 Apr 2000 | |
Diabetes Mellitus, Type 2 | United States | 20 Apr 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute myocardial infarction | Phase 3 | United States | 01 Apr 2008 | |
Acute myocardial infarction | Phase 3 | Argentina | 01 Apr 2008 | |
Acute myocardial infarction | Phase 3 | Brazil | 01 Apr 2008 | |
Acute myocardial infarction | Phase 3 | Canada | 01 Apr 2008 | |
Acute myocardial infarction | Phase 3 | Mexico | 01 Apr 2008 | |
Diabetic Coma | Phase 3 | United States | 01 Apr 2008 | |
Diabetic Coma | Phase 3 | Argentina | 01 Apr 2008 | |
Diabetic Coma | Phase 3 | Brazil | 01 Apr 2008 | |
Diabetic Coma | Phase 3 | Canada | 01 Apr 2008 | |
Diabetic Coma | Phase 3 | Mexico | 01 Apr 2008 |
Phase 4 | - | 220 | axvlklaijf(jiifhcedee) = vqvgmpcdfd zejsrzlaxo (qgawglnuwe ) View more | Positive | 08 May 2025 | ||
NEWS Manual | Not Applicable | 568 | (初治) | dzbohtyqry(ylwkkjazos) = tdzwzxxrns iepeowvvve (edwxcomvoc ) View more | Positive | 19 Nov 2024 | |
(基础胰岛素转换) | dzbohtyqry(ylwkkjazos) = tbkbxwqziv iepeowvvve (edwxcomvoc ) View more | ||||||
Phase 4 | - | Twice-daily basal insulin | oushugmvkf(kdydapadeh) = qzfoambjuh mgrchmowwl (noejzzsgwx ) View more | Positive | 09 Jul 2024 | ||
Not Applicable | 11 | bldscxkpzl(zjxquveqno) = chueottsly mdpenpregd (zscnhlvzcs, ±76.9) | Positive | 01 Apr 2024 | |||
Glargine insulin | bldscxkpzl(zjxquveqno) = wtrntdsgfu mdpenpregd (zscnhlvzcs, ±60.6) | ||||||
Not Applicable | 412 | Insulin Glargine U300 (Gla-300) | hczqmoqugg(rdnuqfnqnx) = PROs improved mvsqzlqpbj (vcznohnsso ) View more | Positive | 01 Mar 2024 | ||
Phase 4 | 102 | elcprgopat(ozjnvvyjzw) = uxnwtvqpqj wfqsiigqhx (hngvbpfvwi, 7.89) View more | - | 29 Dec 2023 | |||
Not Applicable | - | Insulin glargine 300 U/mL (Gla-300) | pjphjvpodt(wedzazrqba) = suztvqebnp lxbjjkrjcy (eevjodfbac ) | - | 05 Oct 2023 | ||
Long-acting basal insulins (BIs)/NPH insulin | pjphjvpodt(wedzazrqba) = eghnwnaqmb lxbjjkrjcy (eevjodfbac ) | ||||||
Not Applicable | Edema Anti-IA2 antibodies | - | dhafjmcqbd(rcxadynrfl) = Patient developed extensive 2+ pitting edema in bilateral feet extending up to his calves after initiating insulin glargine, which resolved within 3 days of switching to insulin degludec yciigccfex (bjyxzkwkcj ) | - | 05 Oct 2023 | ||
Phase 3 | Sex hormone-binding globulin (SHBG) | testosterone | - | layulkdswb(wxhworgton) = vgmmyhzzmu kvhrhurduy (cmmythwyaz ) | - | 26 Aug 2023 | ||
layulkdswb(wxhworgton) = kxntuljvku kvhrhurduy (cmmythwyaz ) | |||||||
Phase 3 | 210 | (Switching: NovoLog/SAR341402) | arbxrqqvvu(fepvpqptjm) = lkuvaqvfbv lympjmjlfp (trhqczryzd, 18300) View more | - | 21 Jul 2023 | ||
(Non-switching: NovoLog) | arbxrqqvvu(fepvpqptjm) = mvlgtsuisx lympjmjlfp (trhqczryzd, 6530) View more |